References (study period) | Categories | Patient group | Patient perspective inflated cost/patient | Societal perspective inflated cost/patient |
---|---|---|---|---|
Chapman et al. [1] (12 months) | All | All | $2444.17 | $3910.39 |
Gender | Male | $1941.09 | $2817.88 | |
Female | $2926.30 | $4956.03 | ||
Smoking status | Former smokers | $3348.67 | $4702.55 | |
Current smokers | $1357.06 | $2958.41 | ||
Comorbidities | Yes | $2506.92 | $4568.22 | |
No | $2370.68 | $3127.96 | ||
Education status | Less educated | $3043.48 | $4540.89 | |
More educated | $2142.85 | $3638.46 | ||
Wouters et al. [37] (1 year) | All | All | $2378.59 | $6693.37 |
Gender | Male | NR | $2741.62 | |
Female | NR | $4254.24 | ||
Smoking status | Former smokers | NR | $4575.67 | |
Current smokers | NR | $2877.75 | ||
Education status | Less educated | NR | $4418.73 | |
Well educated | NR | $3539.53 | ||
Mittmann et al. [3] (52 weeks) | Moderate exacerbation | ITT population | $718.48 | NR |
Clinically evaluable population | $847.38 | NR | ||
Severe exacerbation | ITT population | 10,712.14 | NR | |
Clinically evaluable population | 11,156.01 | NR | ||
Maleki-Yazdi et al. [59] (Oct 2009 and Jan 2010) | All | All | $4391.16 | NR |
Acute exacerbation | Clinically evaluable population | $3214.75 | NR |